PubMed

Effect of telmisartan on renal outcomes: a randomized trial.

Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators.

Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. Epub 2009 May 18.PMID: 19451556 [PubMed - indexed for MEDLINE]Related articles

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators.

Lancet. 2008 Aug 16;372(9638):547-53.PMID: 18707986 [PubMed - indexed for MEDLINE]Related articles

Telmisartan did not prevent renal disease in patients without proteinuria.

[No authors listed]

Ann Intern Med. 2009 Jul 7;151(1):I28. Epub 2009 May 18. No abstract available. PMID: 19451555 [PubMed - indexed for MEDLINE]Related articlesFree article

The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.

Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S.

J Int Med Res. 2005 Nov-Dec;33(6):677-86.PMID: 16372586 [PubMed - indexed for MEDLINE]Related articles

Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.

Barnett A.

J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S132-5.PMID: 16565237 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.

Aranda P, Segura J, Ruilope LM, Aranda FJ, Frutos MA, López V, López de Novales E.

Am J Kidney Dis. 2005 Dec;46(6):1074-9.PMID: 16310573 [PubMed - indexed for MEDLINE]Related articles

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. Epub 2008 Mar 31.PMID: 18378520 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P.

Lancet. 2008 Sep 27;372(9644):1174-83. Epub 2008 Aug 29. Erratum in: Lancet. 2008 Oct 18;372(9647):1384. PMID: 18757085 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

Ann Intern Med. 2003 Apr 1;138(7):542-9.PMID: 12667024 [PubMed - indexed for MEDLINE]Related articlesFree article

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI investigators.

Nephrol Dial Transplant. 2008 Oct;23(10):3174-83. Epub 2008 May 1.PMID: 18450829 [PubMed - indexed for MEDLINE]Related articles

Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.

Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM.

Am J Kidney Dis. 2009 Apr;53(4):606-16. Epub 2009 Feb 12.PMID: 19216016 [PubMed - indexed for MEDLINE]Related articles

Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.

Barnett AH.

Acta Diabetol. 2005 Apr;42 Suppl 1:S42-9. Review.PMID: 15868119 [PubMed - indexed for MEDLINE]Related articles

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Kidney Int. 2004 Jun;65(6):2309-20.PMID: 15149345 [PubMed - indexed for MEDLINE]Related articles

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group.

N Engl J Med. 2004 Nov 4;351(19):1952-61. Epub 2004 Oct 31. Erratum in: N Engl J Med. 2005 Apr 21;352(16)1731. PMID: 15516696 [PubMed - indexed for MEDLINE]Related articlesFree article

The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.

Vogt L, Navis G, Köster J, Manolis AJ, Reid JL, de Zeeuw D; Angiotensin II Receptor Antagonist Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS) Study Group.

J Hypertens. 2005 Nov;23(11):2055-61.PMID: 16208149 [PubMed - indexed for MEDLINE]Related articles

Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).

Diener HC, Sacco R, Yusuf S; Steering Committee; PRoFESS Study Group.

Cerebrovasc Dis. 2007;23(5-6):368-80. Epub 2007 Feb 26. Erratum in: Cerebrovasc Dis. 2008;25(1-2):192. PMID: 17337887 [PubMed - indexed for MEDLINE]Related articles

Prevention of loss of renal function over time in patients with diabetic nephropathy.

Barnett A.

Am J Med. 2006 May;119(5 Suppl 1):S40-7. Review.PMID: 16563947 [PubMed - indexed for MEDLINE]Related articles

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.

Bichu P, Nistala R, Khan A, Sowers JR, Whaley-Connell A.

Vasc Health Risk Manag. 2009;5(1):129-40. Epub 2009 Apr 8. Review.PMID: 19436679 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

[No authors listed]

Lancet. 1997 Jun 28;349(9069):1857-63.PMID: 9217756 [PubMed - indexed for MEDLINE]Related articles

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.

van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.

J Hypertens. 2006 Nov;24(11):2285-92.PMID: 17053552 [PubMed - indexed for MEDLINE]Related articles